Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Olaf Stuve"'
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Externí odkaz:
https://doaj.org/article/f9a628f25d8341028390cdd9229f6db3
Autor:
Afsaneh Shirani, Nil Saez-Calveras, Jack P. Antel, Moein Yaqubi, Wayne Moore, Amy L. Brewster, Olaf Stuve
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Multiple lines of evidence suggest a role of inflammation in epilepsy. Seizure incidence in patients with multiple sclerosis (MS) is twofold to threefold higher than the age-matched general population. Objectives: To explore the associati
Externí odkaz:
https://doaj.org/article/8935f835fd054892b36d48d14c69d1c2
Autor:
Laura Airas, Robert A. Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J. Williams, Bernd C. Kieseier, Heinz Wiendl
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effecto
Externí odkaz:
https://doaj.org/article/e3efcb2e0b04417cb13665a1b2416894
Autor:
Peter V. Sguigna, Rehana Z. Hussain, Annette Okai, Kyle M. Blackburn, Lauren Tardo, Mariam Madinawala, Julie Korich, Lori A. Lebson, Jeffrey Kaplan, Amber Salter, Navid Manouchehri, Olaf Stuve
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Individual disease modifying therapies approved for multiple sclerosis (MS) have limited effectiveness and potentially serious side effects, especially when administered over long periods. Sequential combination therapy is a plausible alt
Externí odkaz:
https://doaj.org/article/465ce37b81b44803b43e41e212df0368
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Several studies have demonstrated that early childhood and adolescent obesity are risk factors for multiple sclerosis (MS) susceptibility. Obesity is thought to share inflammatory components with MS through overproduction of pro-inflammat
Externí odkaz:
https://doaj.org/article/744d5f10f528465a86fb872175ee0cba
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Externí odkaz:
https://doaj.org/article/db8b770f1ee146f2ad1249281f0fa12f
Autor:
Michael S. LaCroix, Hilda Mirbaha, Ping Shang, Stephanie Zandee, Chan Foong, Alexandre Prat, Charles L. White, Olaf Stuve, Marc I. Diamond
Publikováno v:
Acta Neuropathologica Communications, Vol 10, Iss 1, Pp 1-7 (2022)
Abstract Relapsing remitting multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system that in many cases leads to progressive MS, a neurodegenerative disease. Progressive MS is untreatable and relentless, and it
Externí odkaz:
https://doaj.org/article/2b41cf94047942ab9711e3f23b2e3533
Autor:
Tara Maria DeSilva, Olaf Stuve
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 16 (2023)
Externí odkaz:
https://doaj.org/article/153fbe2031554e4f9c71bf430555e07d
Autor:
Rebecca I. Spain, Andrea Hildebrand, Carin S. Waslo, William D. Rooney, Joshua Emmons, Daniel L. Schwartz, Mark S. Freedman, M. Mateo Paz Soldan, Pavle Repovic, Andrew J. Solomon, John Rinker, Mitchell Wallin, Jodie K. Haselkorn, Olaf Stuve, Robert H. Gross, Aaron P. Turner
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundCognitive dysfunction and brain atrophy are both common in progressive multiple sclerosis (MS) but are seldom examined comprehensively in clinical trials. Antioxidant treatment may affect the neurodegeneration characteristic of progressive
Externí odkaz:
https://doaj.org/article/f92e810a84084b538afa13a6598b19e5
Autor:
Barbara E. Stopschinski, Rick A. Weideman, Danni McMahan, David A. Jacob, Bertis B. Little, Hsueh-Sheng Chiang, Nil Saez Calveras, Olaf Stuve
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Alzheimer’s disease (AD) is an untreatable cause of dementia, and new therapeutic approaches are urgently needed. AD pathology is defined by extracellular amyloid plaques and intracellular neurofibrillary tangles. Research of the past decades has s
Externí odkaz:
https://doaj.org/article/ed394128eb9149f986db48d541441288